Logo image of FTRP

FIELD TRIP HEALTH LTD (FTRP) Stock Fundamental Analysis

USA - NASDAQ:FTRP - CA31656R1029 - Common Stock

0.8421 USD
+0.01 (+1.07%)
Last: 8/16/2022, 8:00:00 PM
0.8698 USD
+0.03 (+3.29%)
After Hours: 8/16/2022, 8:00:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to FTRP. FTRP was compared to 100 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of FTRP have multiple concerns. While showing a medium growth rate, FTRP is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

FTRP had negative earnings in the past year.
FTRP had negative earnings in each of the past 5 years.
In the past 5 years FTRP always reported negative operating cash flow.
FTRP Yearly Net Income VS EBIT VS OCF VS FCFFTRP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 -10M -20M -30M -40M -50M

1.2 Ratios

Industry RankSector Rank
ROA -53.55%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FTRP Yearly ROA, ROE, ROICFTRP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -20 -40 -60 -80 -100

1.3 Margins

Industry RankSector Rank
OM -1091.39%
PM (TTM) -1125.3%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FTRP Yearly Profit, Operating, Gross MarginsFTRP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 -500 -1K -1.5K -2K

More info and screens

2

2. Health

2.1 Basic Checks

FTRP does not have a ROIC to compare to the WACC, probably because it is not profitable.
FTRP has more shares outstanding than it did 1 year ago.
The debt/assets ratio for FTRP is higher compared to a year ago.
FTRP Yearly Shares OutstandingFTRP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
FTRP Yearly Total Debt VS Total AssetsFTRP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -0.77, we must say that FTRP is in the distress zone and has some risk of bankruptcy.
A Debt/Equity ratio of 0.40 indicates that FTRP is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Altman-Z -0.77
ROIC/WACCN/A
WACC8.25%
FTRP Yearly LT Debt VS Equity VS FCFFTRP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M 100M

2.3 Liquidity

A Current Ratio of 8.20 indicates that FTRP has no problem at all paying its short term obligations.
FTRP has a Quick Ratio of 8.20. This indicates that FTRP is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 8.2
Quick Ratio 8.2
FTRP Yearly Current Assets VS Current LiabilitesFTRP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

FTRP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.25%.
The Revenue has grown by 471.78% in the past year. This is a very strong growth!
EPS 1Y (TTM)-15.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.89%
Revenue 1Y (TTM)471.78%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%225.3%

3.2 Future

Based on estimates for the next years, FTRP will show a small growth in Earnings Per Share. The EPS will grow by 0.94% on average per year.
The Revenue is expected to grow by 99.77% on average over the next years. This is a very strong growth
EPS Next Y-20.59%
EPS Next 2Y-10.54%
EPS Next 3Y-2.39%
EPS Next 5Y0.94%
Revenue Next Year267.08%
Revenue Next 2Y77.85%
Revenue Next 3Y91.55%
Revenue Next 5Y99.77%

3.3 Evolution

FTRP Yearly Revenue VS EstimatesFTRP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 20M 40M 60M
FTRP Yearly EPS VS EstimatesFTRP Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FTRP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year FTRP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FTRP Price Earnings VS Forward Price EarningsFTRP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.58
FTRP Per share dataFTRP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A cheap valuation may be justified as FTRP's earnings are expected to decrease with -2.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.54%
EPS Next 3Y-2.39%

More info and screens

0

5. Dividend

5.1 Amount

FTRP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FIELD TRIP HEALTH LTD

NASDAQ:FTRP (8/16/2022, 8:00:00 PM)

After market: 0.8698 +0.03 (+3.29%)

0.8421

+0.01 (+1.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-15 2022-08-15/amc
Earnings (Next)11-14 2022-11-14
Inst Owners0.03%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap48.97M
Analysts82.22
Price Target50.54 (5901.66%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.03
P/FCF N/A
P/OCF N/A
P/B 0.95
P/tB N/A
EV/EBITDA -0.58
EPS(TTM)-0.7
EYN/A
EPS(NY)-0.9
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.06
BVpS0.89
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.55%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -1091.39%
PM (TTM) -1125.3%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.2
Quick Ratio 8.2
Altman-Z -0.77
F-Score2
WACC8.25%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.89%
EPS Next Y-20.59%
EPS Next 2Y-10.54%
EPS Next 3Y-2.39%
EPS Next 5Y0.94%
Revenue 1Y (TTM)471.78%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%225.3%
Revenue Next Year267.08%
Revenue Next 2Y77.85%
Revenue Next 3Y91.55%
Revenue Next 5Y99.77%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A